AuroMedics Pharma is voluntarily recalling two lots of Piperacillin and Tazobactam for Injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level.
The products have been found to contain particulate matter, visible only after reconstitution that was confirmed to be glass within the vial. The administration of a glass particulate, if present in an intravenous drug, may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening.
To date, AuroMedics Pharma has not received reports of any adverse events or identifiable safety concerns attributed to the product consumed from these lots.
Home
- About
- Careers
- Contact Us
- Medicare Quality Improvement (QIO)
- HSAG HQIC Partnership
-
ESRD Networks Home
- About Us
- Contact Us
- For Patients and Families
- For Providers
- ESRD Network 7
- ESRD Network 13
- ESRD Network 15
- ESRD Network 17
- ESRD Network 18
- HSAG ESRD Alerts, Recalls, and Notices
- Behavioral Health
- Continuing Education
- Data Management
- Emergency Preparedness
- Home Dialysis
- Infection Prevention
- Patient and Family Engagement (PFE)
- Readmissions and Hospitalizations
- Telemedicine
- Transplant
- Vaccinations
- Healthcare Policy and Quality Measurement
- Medicaid External Quality Review
- QPP Service Center
- Surveys
- Audit and Validation Services (HEDIS®/AMP)
- News